Name: rytvela
Price: 298.00 USD

- Overview
  - IL-1 receptor allosteric antagonist.
    Rytvela is an all D peptide derived from an extracellular loop region of the interleukin-1 receptor accessory protein (IL-1RAcP), which acts as an allosteric negative modulator of the ?interleukin-1 receptor (IL-1R). In vitro, rytvela is specific, potent and effective and blocks human thymocyte proliferation with an IC50 of 1 nM, Rytvela does not significantly inhibit NF-κB, but instead it selectively inhibits the IL-1R downstream stress associated protein kinases/transcription factor c-jun and Rho GTPase/Rho-associated coiled coil containing protein kinase signalling pathways. In vivo rytvela is active in models of hyperthermia and inflammatory bowel disease and topically in contact dermatitis. A scrambled control peptide, rytvela scrambled peptide, is also available.
    
    Please contact us for availability.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Peptides
    
    Alternative Name
    
    101.1
    
    Molecular Formula
    
    C38H62N10O12
    
    Molecular Weight
    
    850.96
    
    Appearance
    
    Freeze dried solid
    
    Purity
    
    >95% by HPLC
    
    Solubility
    
    Soluble in water
    
    Other Properties
    
    Sequence: H-(D)Arg-(D)Tyr-(D)Thr-(D)Val-(D)Glu-(D)Leu-(D)Ala-OH,rytvela
    Modification: All amino acids are D isomers
    
    Storage
    
    Store dry, frozen and in the dark
    
    * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

We Also Recommend

rytvela scrambled peptide

$298

S1H

$314

Saralasin

$348

Saralasin

$227